COMMUNIQUÉS West-GlobeNewswire

Alvotech files Annual Report with the SEC
31/03/2026
REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), [...]
ProHealth Longevity BPC‑157 Claims Evaluated: Most Effective BPC157 Peptide Brand on the Market (2026)
30/03/2026
A 2026 consumer information guide examining ProHealth BPC-157 oral peptide capsule details, arginate vs acetate formulation context, preclinical tissue repair research, regulatory status, third-party testing [...]
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
30/03/2026
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of the sale of Cyprium’ [...]
Range Impact Reports Full Year 2025 Financial Results
31/03/2026
CLEVELAND, OHIO, March 30, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mine properties [...]
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
30/03/2026
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in [...]
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
30/03/2026
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first [...]
Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité
30/03/2026
Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025 Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme 1 au 31 décembre 2025 Réalisation d'une [...]
MemoryON Claims Evaluated: Hidden Details Emerge About Memory On Brain Support Supplementation for Memory Loss
31/03/2026
A 2026 informational consumer report on MemoryON's cognitive health formula, Bacopa Monnieri and Phosphatidylserine dosage research, St. John's Wort safety considerations, nootropic ingredient analysis, pricing [...]
Terra Pharm Medical Marijuana Organization Opens Cultivation Facility and Dispensaries in Pennsylvania
30/03/2026
Pennsylvania’s newest medical marijuana organization partners with Duquesne University Nasuti College of Osteopathic Medicine on evidence-based research. PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Terra Pharm, [...]
Children’s National Hospital announces new pain management center to help children and their families reclaim their lives from chronic pain
30/03/2026
Supported by an $8.895 million investment, new center will deliver comprehensive, multidisciplinary care for children and adolescents experiencing acute and chronic pain Washington, DC, March 30, 2026 (GLOBE NEWSWIRE [...]
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
30/03/2026
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an [...]
IBA – ACQUISITION D’ACTIONS PROPRES
30/03/2026
Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
IBA – ACQUISITION OF OWN SHARES
30/03/2026
Louvain-la-Neuve, Belgium, March 30 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Supported by significant progress in the financing of its industrial project in France, Carbios confirms its objective to build the Longlaville plant
30/03/2026
Carbios confirms its objective for the Longlaville plant construction project, within a project financing framework and a target of starting production by H1 2028. Carbios has a solid cash position, with around €60 [...]
Major Shareholder Announcement
30/03/2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis [...]
Grâce à des avancées significatives dans le financement de son projet industriel en France, Carbios confirme son objectif de construction de l’usine de Longlaville.
30/03/2026
Carbios confirme son objectif concernant le projet de construction de l’usine de Longlaville, dans le cadre d’un financement de projet, avec pour objectif un démarrage de production à horizon S1 2028. Carbios dispose d’ [...]
Chiesi Global Rare Diseases Receives Positive CHMP Opinion for LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)
30/03/2026
Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, with European Commission (EC) decision anticipated by June 1, 2026 If approved, this would expand the indication of lomitapide to include [...]
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
30/03/2026
-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira [...]
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
30/03/2026
Confirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancers Early clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitor Emerging clinical proof [...]

Pages